Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: Systematic review and meta-analysis
Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: Systematic review and meta-analysis
复制标题
DOI：
10.4065/83.1.23
复制
发表时间：
2008-01-01
影响因子：
8.9
通讯作者：
Montori, Victor M.
中科院分区：
文献类型：
--
作者：
Bardia, Aditya;Tleyjeh, Imad M.;Montori, Victor M.
目的：评估抗氧化剂使用与原发性癌症发病率和死亡率之间的关系，并评估这些影响在特定抗氧化剂化合物、靶器官和参与者亚组中的作用。方法：检索多个电子数据库（MEDLINE， Cochrane对照临床试验注册，EMBASE，科学引文索引），从其成立日期到2005年8月，以确定符合条件的随机临床试验。随机效应荟萃分析估计了描述抗氧化剂与安慰剂对癌症发病率和癌症死亡率影响的汇总相对风险（rr）和95%置信区间（ci）。结果：共纳入12项符合条件的试验，其中9项方法学质量较高（受试者总人数104,196人）。补充抗氧化剂并没有显著降低总癌症发病率（IRR, 0.99; 95% CI, 0.94-1.04）或死亡率（RR, 1.03; 95% CI, 0.92-1.15）或任何特定部位的癌症发病率。补充β -胡萝卜素与吸烟者中癌症发病率的增加有关（RR, 1.10; 95% CI, 1.03-1.10），并有增加癌症死亡率的趋势（RR, 1.16; 95% CI, 0.98-1.37）。补充硒与降低男性癌症发病率相关（RR, 0.77; 95% CI, 0.64-0.92），但与女性无关(IRR, 1.00; 95% CI, 0.89-1.13，相互作用值，P
OBJECTIVE: To estimate the association between antioxidant use and primary cancer incidence and mortality and to evaluate these effects across specific antioxidant compounds, target organs, and participant subgroups.METHODS: Multiple electronic databases (MEDLINE, Cochrane Controlled Clinical Trials Register, EMBASE, Science Citation Index) were searched from their dates of inception until August 2005 to identify eligible randomized clinical trials. Random effects meta-analyses estimated pooled relative risks (RRs) and 95% confidence intervals (CIs) that described the effect of antioxidants vs placebo on cancer incidence and cancer mortality.RESULTS: Twelve eligible trials, 9 of high methodological quality, were identified (total subject population, 104,196). Antioxidant supplementation did not significantly reduce total cancer incidence (IRR, 0.99; 95% CI, 0.94-1.04) or mortality (RR, 1.03; 95% CI, 0.92-1.15) or any site-specific cancer incidence. Beta carotene supplementation was associated with an increase in the incidence of cancer among smokers (RR, 1.10; 95% CI, 1.03-1.10) and with a trend toward increased cancer mortality (RR, 1.16; 95% CI, 0.98-1.37). Selenium supplementation was associated with reduced cancer incidence in men (RR, 0.77; 95% CI, 0.64-0.92) but not in women (IRR, 1.00; 95% CI, 0.89-1.13, value for interaction, P